Point-Of-Care Glucose Testing Market Size & Share Analysis - Growth Trends And Forecast (2026 - 2031)

Continuous and flash sensors are moving the point of care glucose testing market away from episodic strip-based checks. Lancing devices and strips still commanded 60.92% of point of care glucose testing market size in 2025, but sensor shipments are expanding at 4.76% CAGR as providers seek richer glycemic profiles. Dexcom’s G7 posts a mean absolute relative difference of 8.2%, the best among FDA-cleared CGMs, prompting formularies to include sensors for both inpatient and outpatient populations. Meanwhile, Roche enhances strip accuracy through novel enzymatic chemistry and couples it with native EMR connectivity, prolonging relevance for conventional meters.

Clinical performance drives purchase decisions. Hospitals value sensors’ predictive-alert capability, which flags impending hypo- or hyper-glycemia and triggers protocol-based interventions. Conversely, emerging markets continue to favor strips because of lower upfront cost and reliable reimbursement. Manufacturers counter by offering hybrid kits—strip meters with optional Bluetooth modules—to create upgrade paths while preserving affordability. The interplay sustains diverse product mixes across regions, preventing dominance by a single technology while widening patient choice.

Type-2 cohorts dominate testing volume, representing 84.12% of all strip and sensor sales in 2025. However, point of care glucose testing market share for type-1 diabetes applications is growing more swiftly, propelled by automated insulin delivery systems that hinge on real-time sensor input. Medtronic’s MiniMed 780G coupled with the Simplera Sync disposable sensor earned CE-Mark in January 2025, allowing calibration-free use and driving pediatric adoption in Europe.

Gestational-diabetes monitoring, though smaller in absolute dollars, garners policy emphasis because rigorous glucose control mitigates neonatal complications. ADA’s 2025 Standards of Care instruct obstetric teams to adopt frequent point-of-care monitoring during pregnancy, fostering demand for intuitive meters that sync with prenatal electronic records. Vendors respond with color-coded trend indicators and scheduled reminder alarms, features that enhance adherence in a time-limited clinical scenario.

Hospitals and clinics controlled 53.84% of 2025 revenue, leveraging networked meters for in-house glucose rounding, intensive-care oversight, and pre-surgical screening. COVID-19 accelerated interest in minimally invasive sensors, enabling nurses to capture values without repeated room entry. Adoption persists as facilities benchmark reduced staff workload and sample-handling errors.

Home-care users are the fastest-growing cohort at 5.42% CAGR. The FDA’s June 2024 authorization of Abbott’s Libre Rio and general-consumer Lingo sensors for OTC sale broadened eligibility beyond insulin-dependent patients. Combined with smartphone dashboards and cloud-delivered coaching, home users can share longitudinal data with physicians, aligning with payer programs that reward remote monitoring. Vendors additionally market subscription models bundling sensors, lancets, and AI-guided feedback, turning device revenue into recurring service streams.

Prescription devices still comprise 68.87% of global units due to clinician oversight requirements and legacy reimbursement structures. Hospitals and endocrinologists value the ability to tailor meter selection based on comorbidities and user dexterity.

The OTC channel, however, is tilting the landscape. Dexcom’s Stelo sensor, cleared in March 2024, targets non-insulin consumers who previously relied on boutique wellness trackers, offering medical-grade accuracy without a doctor’s visit. Analysts expect OTC to approach 39.50% share by 2031 as retailers stock sensors alongside blood-pressure and pulse-ox devices, positioning pharmacies as decentralized diagnostics hubs. Manufacturers are partnering with chain stores for installment-based payment plans to mitigate up-front cost, widening demographic reach.

North America accounted for 40.12% of worldwide point of care glucose testing market size in 2025, underpinned by high disease prevalence, advanced reimbursement, and rapid uptake of CGMs. CMS broadened sensor coverage to all insulin users in 2024, removing cost barriers for 1.5 million Medicare beneficiaries and reinforcing double-digit growth for connected solutions. Device makers also benefit from a vibrant digital-health ecosystem that integrates readings with tele-endocrinology platforms, elevating clinical value and patient loyalty.

Europe stands as the second-largest region. Structured procurement in national health systems promotes early technology adoption once cost-effectiveness is demonstrated. The CE-Mark approval of Medtronic’s MiniMed 780G with disposable sensor affirms regulators’ receptivity to hybrid closed-loop designs. Yet, the European Commission’s 2024 study revealing that 87% of public tenders contained import-restrictive clauses could temper non-EU supplier entry, nudging vendors toward local manufacturing.

Asia Pacific is the fastest-growing territory, forecast at a 6.23% CAGR from 2026-2031. Government screening programs, such as India’s National Diabetes Programme, introduce millions to first-time testing each year. Rising middle-class income supports sensor upgrades among urban populations, while smartphone penetration enables app-based coaching even in semi-urban settings. Challenges remain: fragmented reimbursement and uneven clinician distribution slow diffusion in rural areas, but low-cost Bluetooth meters offered below USD 20 per kit are narrowing the access gap.